Liraglutide 3mg (Saxenda) trial targets weight, body composition, and hormonal improvements in obese women with PCOS

There is a significant need for effective pharmacologic interventions to improve metabolic function in women with Polycystic Ovary Syndrome (PCOS). This common condition is often accompanied by obesity, where weight loss is crucial but notoriously difficult to achieve. While high-dose liraglutide has shown significant weight reduction in obese women without PCOS, data on its efficacy in non-diabetic females with PCOS is limited. Current research lacks comprehensive studies on anti-obesity medications, alone or combined with lifestyle changes, for improving body weight, composition, and androgen excess in this specific population.

Investigators are conducting a Phase 3 randomized clinical trial (NCT05965908) enrolling 150 obese women diagnosed with PCOS. The study aims to evaluate the effects of Liraglutide 3mg (Saxenda) on body weight, body composition, and various hormonal and metabolic parameters. Participants are expected to receive Liraglutide 3mg daily via subcutaneous injection, following standard clinical protocols for weight management. The primary endpoints include changes in body weight, body composition, and key markers of androgen excess and overall metabolic health, compared to a likely placebo or standard care arm.